A Phase 2, randomized, multicenter, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and population PKs of once-daily oral E5501 tablets used up to 7 days in subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures

ID Number 09-1961

Principal Investigator(s)
Charissa Chang

Department(s) or Division(s)


Thrombocytopenia (low platelet levels) is a common problem in patients with chronic liver disease. The current Phase 2 study will evaluate several doses of E5501 to treat preoperative thrombocytopenia in these patients. The study design considers a dosing regimen that includes a loading dose followed by a short term treatment period that is anticipated to lead to a rapid rise in platelet counts, enabling subjects to complete their scheduled procedure without the need for platelet transfusion.

Contact Information
Sherif Mikhail
(212) 659-8039

Recruiting Patients: Yes